Groprinosin is an immunostimulating agent with antiviral activity.
Release form and composition
The active ingredient Groprinosina is inosine pranobex.
The drug is available in the form of tablets and syrup.
One tablet of Groprinosin contains 0.5 grams of inosine pranobex, as well as povidone, magnesium stearate, and potato starch as auxiliary components. Implemented tablets of 10 pcs. in blisters, 1, 2 or 5 blisters in the package.
The composition of syrup inosine pranobex is included in a concentration of 50 mg per 1 ml. Auxiliary substances: methyl- and propylhydroxybenzoate (respectively, E218 and E216), sucrose, saccharin sodium, glycerin, ethyl alcohol 96%, raspberry flavor, purified water.
Indications for use
Groprinosin, according to the instructions used for the treatment of:
- Viral infections in patients with normal and reduced immune status, including ARVI, influenza, parainfluenza, viral bronchitis, epidemic parotitis, rhinosurve and adenovirus infections, measles (including if the disease is complicated or severe);
- Diseases provoked by the activity of herpes viruses of type HSV-1 or HSV-2 (including herpes lips, ophthalmic herpes, herpes mucous oral cavity, face skin and hands), genius herpes, leukoencephalitis Van-Bogart (subacute sclerosing encephalitis);
- Diseases that are caused by the activity of herpesvirus type HHV-3 - chickenpox and herpes zoster, including recurrent disease and in people with immunodeficiency;
- Diseases caused by herpes virus HHV-4 (Epstein-Barr virus), including mononucleosis;
- Diseases associated with cytomegalovirus (herpes virus type 5) and human papillomavirus;
- Viral hepatitis B (acute or chronic);
- Chronic recurrent infections of the respiratory and urogenital tracts in immunocompromised patients (including diseases caused by intracellular pathogens, such as chlamydia).
According to the instructions to Groprinosin, the use of the drug is contraindicated in:
- Chronic renal failure;
- Pregnancy and breastfeeding;
- Hypersensitivity to the components of Groprinosin.
In pediatric practice it is prohibited to use the tool for children under 3 years old (or with a weight of up to 15-20 kg).
Caution should be taken when acute renal failure occurs.
Dosing and Administration
Both syrup and Groprinosin tablets should be taken after meals, keeping at regular intervals between doses. If necessary, the tablet is allowed to chew, grind or dissolve in a small amount of liquid just before taking.
The treatment regimen is selected individually depending on the type of pathogen, the severity of the pathological process, the nosology of the disease, the frequency of relapses, the age and weight of the patient. Adults per day appoint 6-8 tablets, divided respectively into 3 or 4 doses.
The course of Groprinosin usually varies from 5 days to 2 weeks. After the complete disappearance of the symptoms of the disease, the treatment should be continued for a day or two (sometimes more, according to indications).
In chronic recurrent diseases, Groprinosin is taken in courses of 5-10 days, with 7-10 days breaks in between.
Maintenance therapy (in this case, the dosage of the drug is reduced to 0.5-1 grams per day, that is, up to 1-2 tablets) and treatment with interruptions can last from 30 days to six months.
The maximum daily dose for adults is 4 grams, which corresponds to 8 tablets (or 80 ml of syrup). In severe cases of the disease, the dose of Groprinosin for adults can be increased to 100 mg / kg per day. In this case, divide it into 4-6 receptions.
For children from 3 to 12 years old, the drug is prescribed at the rate of 50 mg / kg / day, in severe cases it can be increased. The multiplicity of techniques - 3-4 times a day.
The most frequent side effects that develop with Groprinosin are:
- Deterioration of general well-being;
- Increased fatigue;
- Stomach ache;
- Nausea and vomiting;
- Loss of appetite;
- Increased activity of liver enzymes, as well as the enzyme ALP (alkaline phosphatase);
- Skin rash and itching;
- Joint pain;
- Aggravation of gout;
- Increased serum urea concentration.
Slightly less use of the drug is accompanied by drowsiness or insomnia, nervousness, diarrhea or constipation, polyuria, urticaria, maculopapular rash, angioedema.
In the event of an overdose of Groprinosin, first aid for the victim should be gastric lavage. Further treatment is symptomatic.
The use of the drug in combination:
- With immunosuppressants - helps to reduce the immunostimulating action of Groprinosin;
- With loop diuretics and xanthine oxidase inhibitors - is fraught with an increase in serum uric acid levels;
- With zidovudine - leads to an increase in its plasma concentration and prolongation of the half-life.
Dizziness and drowsiness are possible side effects of Groprinosin with potentially dangerous consequences. This should be considered by people driving a car or working with complex machinery.
Structural analogue - Isoprinosine.
The group of drugs that are close to the mechanism of action include: Allokin-alpha, Amizon, Arbidol, Viracept, Hyporamine, Ingavirin, Kagocel, Nikavir, Oksolin, Panavir, Proteflazid, Ferrovir, Ergoferon.
Terms and conditions of storage
Groprinosin - belongs to the category of medicines dispensed from pharmacies by prescription.
The drug should be stored at temperatures up to 25 ºC. The shelf life of the tablets is 36 months, the syrup is 24 months, after opening the bottle is 24 days.